Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Shareholder Meeting (November 2021)
19 slides from Island Pharmaceuticals's shareholder meeting presentation, Nov 17, 2021
Slide 1: MD Presentation, Dr David Foster, CEO & MD
For personal use only MD PRESENTATION, DR DAVID FOSTER, CEO & MD ISLAND PHARMACEUTICALS LIMITED 1 Investor INVESTOR Presentation PRESENTATION – October 2021 – OCTOBER 2021
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Island Pharmaceuticals Limited views on its future performance or condition. Actual results could differ No representation, warranty or assurance (express or implied) is given For personal use only (ABN 641 183 842) (Company or Island Pharmaceuticals
Slide 3: Upcoming Milestones
UPCOMING MILESTONES For personal use only H1 FY 2022 H2 FY 2022 H1 FY 2023 Sign SUNY CTA • Complete clinical product • Advance through PEACH Announce Principal • File IND cohorts Investigator • Open IND • Trial read out • Screening subjects for • Meeting with FDA • Engage CRO • Identify lead mol
Slide 4: Island at a Glance
ISLAND AT A GLANCE For personal use only Island Pharmaceuticals (ASX: ILA) is a mid clinical-stage drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases Island’s drug Island repurposing Initial focus is Pharmaceuticals strategy on mosquito lists
Slide 5: The Benefits of Drug Repurposing
THE BENEFITS OF DRUG REPURPOSING For personal use only ISLAND PHARMACEUTICALS LIMITED 5 Investor INVESTOR Presentation PRESENTATION – October 2021 AGM – NOVEMBER – OCTOBER 2021
Slide 6: ISLA-101 Repurposed Drug Dramatically Reduces Development Time, Risk and Cost
ISLA-101 REPURPOSED DRUG DRAMATICALLY REDUCES DEVELOPMENT TIME, RISK AND COST For personal use only Strong regulatory Speed to market ISLA-101, originally Demonstrated Capitalising on history and & early revenue a cancer drug as safe in humans millions spent acceptance potential Originally identifie
Slide 7: ISLA-101 Broad Activity Evident
ISLA-101 BROAD ACTIVITY EVIDENT DEMONSTRATED ACTIVITY AGAINST FLAVIVIRUSES IN MULTIPLE MODELS OF INFECTION For personal use only Dengue 1-4 • In in-vitro models using fresh human cells, ISLA-101 has demonstrated broad anti-viral activity Zika • In animal models, ISLA-101 is protective in dengue feve
Slide 8: Safety Profile of Drug Established
SAFETY PROFILE OF DRUG ESTABLISHED 45 HUMAN CLINICAL STUDIES OF ISLA-101 COMPLETED IN OTHER INDICATIONS For personal use only 4 2 Canada EU Verified as safe in 1 humans by multiple 1 Asia 39 regulators in other Middle US clinical indications East 3 Australia & NZ ISLAND PHARMACEUTICALS LIMITED 8 INV
Slide 9: Phase II Dengue (PEACH) Trial Study in Detail
PHASE II DENGUE (PEACH) TRIAL STUDY IN DETAIL “PEACH" STUDY- A PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY FOR THE PROPHYLACTIC EXAMINATION OF AN ANTIVIRAL IN A DENGUE CHALLENGE MODEL For personal use only Administer ISLA-101 daily Phase II trial protocol Up to 4 cohorts/4 arms Incl
Slide 10: Platform Strategy: Multiple Shots on Goal
PLATFORM STRATEGY: MULTIPLE SHOTS ON GOAL For personal use only TARGETS • Tropical diseases with no existing therapies • Prophylactic or therapeutic trial potential ISLAND PHARMACEUTICALS LIMITED 10 Investor INVESTOR Presentation PRESENTATION – October 2021 AGM – NOVEMBER – OCTOBER 2021
Slide 11: Priority Review Voucher Eligibility
PRIORITY REVIEW VOUCHER ELIGIBILITY For personal use only The last 10 PRV acquisitions • ISLA-101 is eligible for Neglected Tropical Date Acquired by Value Disease designation for the treatment of Q3 2019 Astra Zeneca US$95m dengue fever Q4 2019 Confidential US$95m • This designation means ISLA-101
Slide 12: Commercial Opportunity
COMMERCIAL OPPORTUNITY For personal use only Prophylactic for National Government Priority Review travelers Military outbreaks Stockpiles Voucher Tropical area travellers opportunity: Endemic area opportunity: Military opportunity: • Annual market many millions of • Many millions of patients in Cent
Slide 13: Monash University Collaboration
MONASH UNIVERSITY COLLABORATION INITIAL LICENSE FOR LEAD PROGRAM AND PIPELINE EXPANSION For personal use only Monash University • Isla US initially licensed intellectual property (IP) created by Monash University. IP was produced as part of a research project undertaken by Monash University that led
Slide 14: Griffith University Collaboration
GRIFFITH UNIVERSITY COLLABORATION BOOST PIPELINE DEVELOPMENT For personal use only On the 23 August 2021 Island Pharmaceuticals (ASX: ILA) announced a Anti-Viral Molecule Screening Collaboration with Griffith University. • The new drug research collaboration focuses on repurposing small molecules wi
Slide 15: Drug Development Pipeline
DRUG DEVELOPMENT PIPELINE For personal use only Stage of Development Program Indication Preclinical Phase I Phase 2 Phase 3 FDA Review Dengue (PEACH) To be initiated ISLA-101 Other mosquito (or vector) borne diseases Monash TBD Collaboration Griffith TBD Collaboration ISLAND PHARMACEUTICALS LIMITED
Slide 16: Key Collaborations & Alliances
KEY COLLABORATIONS & ALLIANCES SUPPORTING FUTURE PIPELINE DEVELOPMENT For personal use only Research Collaboration Agreement to screen thousands of known molecules against host targets building upon the Fenretinide (ISLA-101) discovery sourced from these laboratories that the Company has licensed fo
Slide 17: Board, Management & Scientific Board
BOARD, MANAGEMENT & SCIENTIFIC BOARD ISLAND IS LED BY A HIGHLY CAPABLE, EXPERIENCED MANAGEMENT TEAM, BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD WITH EXTENSIVE EXPERTISE IN DRUG REPURPOSING AND For personal use only DEVELOPMENT, INFECTIOUS DISEASES AND EXECUTING SUCCESSFUL COMMERCIAL TRANSACTIO
Slide 18: Key Strengths
KEY STRENGTHS For personal use only Initially targeting Drug repurposing Phase II Commercial Pipeline Highly dengue diseases strategy ready asset upside expansion experienced with unmet need strategy team Targeting diseases, Repurposing can Lead compound, Potential ‘platform Research Experienced Boa
Slide 19: For personal use only
For personal use only David Foster Chief Executive Officer & Executive Director david@islapharma.com Island Pharmaceuticals www.islapharma.com Registered office: Suite 201, 697 Burke Rd, Camberwell VIC 3124, Australia Limited Approved ISLAND for release by PHARMACEUTICALS Paul MacLeman LIMITED 19 In
Island Pharmaceuticals — Shareholder Meeting (November 2021) on 6ix